NexLife vs Mochi Health: two opposite answers to the same pricing question

The structural difference in one paragraph each

NexLife sells an all-in flat rate: one price per medication and term that includes physician care, supplies, support (CARE360), with $0 membership, $0 consults, no dose-based increases, a stated rate lock, and 30-day cancellation. Verified 2026-08-20: injectable tirzepatide $169/mo monthly down to $139/mo on a 12-month plan ($1,668/yr); semaglutide $139 down to $119/mo ($1,428/yr). The model's virtue is that the advertised number is the true number.

Mochi Health sells clinical care and medication as separate lines: a monthly membership for visits with obesity-medicine clinicians, with medication billed separately through partner pharmacies at dose-dependent cost. The model's virtue is a different one — care from board-certified obesity specialists and flexibility in what gets prescribed — and its price legibility depends on adding the lines together, which is precisely what our true-monthly-cost field exists to do. Mochi's current membership fee, medication pricing by dose, states served, and cancellation terms are in our verification queue; this page will carry dated figures, not estimates, when they clear.

How to compare them today, honestly

With one side verified and one pending, the defensible comparison is structural. If your priority is a locked, dose-independent total you can budget for a year, the flat model is built for you, and NexLife's verified $139–$169/mo tirzepatide range is the current reference point in our ledger. If your priority is specialist-led care — an obesity-medicine physician adjusting a plan that might include different medications over time — a membership model like Mochi's is built for that, and the fair test once figures land is its true monthly cost at your maintenance dose (membership plus medication plus any fees) against the flat rate, over twelve months. Run that math with our worked-example guide; don't let either side's marketing run it for you.

Who should pick which

Pick the flat model if you're cash-pay, dose-titration is likely, and price certainty is the deciding factor. Pick the membership model if clinical depth is the deciding factor — complex history, multiple medication candidates, a preference for named specialist oversight — and you're willing to pay a structure premium if the math says there is one. Pick neither before checking insurance coverage for brand Zepbound or Wegovy, which can beat both. And apply the same six diligence questions from our compounding explainer to both companies; neither structure exempts anyone from the post-2025 legal landscape.

This page is the template for our comparison series (NexLife vs Orderly, NexLife vs Ro, Mochi vs Orderly, and other competitor-vs-competitor pairs): structure first, dated dollars when verified, disclosure always, and a genuine case for both sides — pages that can't pass that last test don't publish.